Stay updated on NUC-7738 in Advanced Solid Tumours: Clinical Trial

Sign up to get notified when there's something new on the NUC-7738 in Advanced Solid Tumours: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NUC-7738 in Advanced Solid Tumours: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the Phase I/II study of NUC-7738, where the dose-escalation and expansion study now includes evaluating NUC-7738 monotherapy across different administration schedules and in combination with pembrolizumab for patients with advanced solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:30.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying inclusion and exclusion criteria for different cohorts in the study. This change provides more comprehensive information about the health conditions and prior treatments required for participation.
    Difference
    48%
    Check dated 2024-05-22T21:19:26.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:43:08.000Z thumbnail image

Stay in the know with updates to NUC-7738 in Advanced Solid Tumours: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NUC-7738 in Advanced Solid Tumours: Clinical Trial page.